Latanoprostene Bunod Ophthalmic
Latanoprostene bunod ophthalmic solution is a prostaglandin analog eye drop used to lower elevated eye pressure in adults with open-angle glaucoma or ocular hypertension.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Latanoprostene Bunod Ophthalmic: Patient Information Guide
A plain-language walkthrough of Latanoprostene Bunod Ophthalmic — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Latanoprostene bunod ophthalmic solution is approved to lower intraocular pressure (pressure inside the eye) in adults. Specifically:
- Vyzulta 0.024% eye drops are indicated for reducing intraocular pressure in adults with open-angle glaucoma
- Vyzulta 0.024% eye drops are indicated for reducing intraocular pressure in adults with ocular hypertension (elevated eye pressure without glaucoma damage)
⚙️How it works▾
After you apply the drop, latanoprostene bunod is rapidly converted inside the eye into two active compounds: latanoprost acid, a prostaglandin analog, and butanediol mononitrate, which releases nitric oxide. Latanoprost acid promotes drainage of aqueous humor (the fluid inside the eye) through both the trabecular meshwork and the uveoscleral pathway. Nitric oxide helps relax the trabecular meshwork tissue, making it easier for fluid to flow out. Less fluid buildup means lower pressure inside the eye, which reduces the risk of glaucoma progression and vision loss.
💊How it's taken▾
Vyzulta is applied as one drop into the affected eye or eyes once each evening. Using it more than once a day can actually weaken its pressure-lowering effect, so stick to the evening routine.
- If you use other eye drops for eye pressure, separate each one by at least 5 minutes
- Remove contact lenses before applying; wait 15 minutes before reinserting them
- Follow your prescriber's specific instructions — do not adjust your own dose or timing
🤒Side effects — in detail▾
The most common side effects with Vyzulta are eye-related and generally mild:
- Red or pink eyes (conjunctival hyperemia) — seen in about 6% of people
- Eye irritation — about 4%
- Eye pain — about 3%
- Stinging at the time of application (instillation site pain) — about 2%
- Gradual darkening of the iris (eye color change) — may be permanent
- Eyelash changes: longer, thicker, or more lashes — usually reversible after stopping
Contact your doctor right away if you develop worsening eye redness, pain, blurred vision, or signs of infection — these can signal a more serious problem like eye inflammation, macular edema, or bacterial keratitis.
⚠️Warnings & precautions▾
- Permanent iris darkening: Vyzulta can slowly increase brown pigment in the iris. This is likely permanent even after you stop the medication. Regular eye exams help track any changes.
- Eyelid and eyelash changes: Skin around the eye may darken, and lashes may grow longer or thicker. These changes are usually reversible when treatment stops.
- Eye inflammation: Use with caution if you have a history of iritis or uveitis; avoid if inflammation is currently active, as Vyzulta may make it worse.
- Macular edema: Swelling in the central retina has been reported with prostaglandin analogs. Extra caution is needed if you've had certain types of cataract surgery or have other risk factors.
- Bacterial keratitis (eye infection): Do not touch the dropper tip to your eye or any surface — contamination of the bottle has been linked to serious eye infections, especially when the eye surface is compromised.
- Contact lenses: Always remove lenses before applying Vyzulta; the preservative (benzalkonium chloride) can be absorbed by lenses. Wait 15 minutes before putting lenses back in.
🔀What it interacts with▾
There are limited systemic drug interactions because Vyzulta is applied directly to the eye, but there are two important practical considerations:
- Other eye pressure-lowering drops: Space them at least 5 minutes apart from Vyzulta — mixing drops too close together can reduce effectiveness
- Contact lenses: Benzalkonium chloride, the preservative in Vyzulta, is absorbed by soft contact lenses and could irritate the eye — always remove lenses first and wait 15 minutes after dosing
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Eye inflammation (iritis/uveitis): Tell your doctor if you have a history of this — Vyzulta needs extra caution and should generally not be used during active flare-ups
- Macular edema risk: Alert your doctor if you have had cataract surgery (especially with a torn posterior lens capsule) or other known risk factors for retinal swelling
- Pregnancy: Animal studies showed serious fetal harm at relatively low doses. There are no human data. Tell your doctor if you are pregnant or trying to conceive before using Vyzulta.
- Breastfeeding: It is unknown whether Vyzulta passes into breast milk. Discuss risks and benefits with your doctor.
- Children 16 and younger: Vyzulta is not recommended for pediatric patients due to concerns about long-term pigmentation effects from chronic use.
- Older adults (65+): No dose adjustment is needed — safety and effectiveness are similar to younger adults.
📡Pharmacodynamics — effects in the body▾
After the first dose of Vyzulta, intraocular pressure starts to fall within about 1 to 3 hours. The maximum pressure-lowering effect is reached roughly 11 to 13 hours after administration in eyes with elevated pressure. This is why the drop is taken in the evening — the peak effect lines up with the overnight hours when eye pressure can tend to rise.
🔬Pharmacokinetics — how your body processes it▾
When applied to the eye, latanoprostene bunod is rapidly broken down into its active components: latanoprost acid and butanediol mononitrate. Latanoprost acid reaches peak levels in the bloodstream in about 5 minutes after dosing, but blood concentrations are very low and clear quickly — falling below detectable limits in most people within 15 minutes. Latanoprost acid is then processed primarily by the liver. Butanediol mononitrate breaks down into nitric oxide and other byproducts that enter normal metabolic pathways. The overall systemic exposure is minimal with once-daily eye drop use.
📦How to store it▾
Unopened bottle should be stored refrigerated at 2°C to 8°C (36°F to 46°F). stored at 2°C to 25°C (36°F to 77°F) for 8 weeks. Protect from light.
📄 Written from Latanoprostene Bunod Ophthalmic’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Latanoprostene Bunod Ophthalmic — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Vyzulta used for? ▾
Why does it need to be used in the evening? Can I use it in the morning instead? ▾
Will Vyzulta change the color of my eyes permanently? ▾
Can I use Vyzulta with my contact lenses in? ▾
Are there side effects I should watch out for beyond the usual eye irritation? ▾
Is Vyzulta safe to use during pregnancy or while breastfeeding? ▾
Is Latanoprostene Bunod Ophthalmic available over the counter? ▾
When was Latanoprostene Bunod Ophthalmic first available? ▾
💬 Answers drafted from Latanoprostene Bunod Ophthalmic’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Latanoprostene Bunod Ophthalmic comes
Latanoprostene Bunod Ophthalmic is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Eye drops
How this form is used
- Vyzulta is used to reduce intraocular pressure in adults with open-angle glaucoma
- Vyzulta is used to reduce intraocular pressure in adults with ocular hypertension
- Vyzulta: instill one drop into the affected eye(s) once daily in the evening
- Vyzulta: do not use more than once daily — more frequent use may reduce its pressure-lowering effect
- Vyzulta: if using alongside other eye drops, wait at least 5 minutes between each product
- Vyzulta: remove contact lenses before applying; wait 15 minutes before reinserting them (the preservative benzalkonium chloride can be absorbed by lenses)
📊 Latanoprostene Bunod Ophthalmic across the U.S. market
How Latanoprostene Bunod Ophthalmic appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Latanoprostene Bunod Ophthalmic is used
A general measure of how commonly Latanoprostene Bunod Ophthalmic is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Latanoprostene Bunod Ophthalmic is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Latanoprostene Bunod Ophthalmic prescribed? Of the 1,594 medications we measure, Latanoprostene Bunod Ophthalmic ranks #875 by Medicaid prescriptions — more than 45% of them.
Utilization by Latanoprostene Bunod Ophthalmic product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
latanoprostene bunod 0.24 MG/ML Ophthalmic Solution
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1988394
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Latanoprostene Bunod Ophthalmic, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 2 of 6 listed Latanoprostene Bunod Ophthalmic NDCs with Medicaid activity.
🔍 Compare Latanoprostene Bunod Ophthalmic products
A representative set of FDA-listed product records for Latanoprostene Bunod Ophthalmic — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 0.24 mg/mL | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | NDA | View NDC → |
Showing 2 of 2 products — FDA National Drug Code Directory. See every product, package size and price: browse all 2 Latanoprostene Bunod Ophthalmic NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Latanoprostene Bunod Ophthalmic — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Latanoprostene Bunod Ophthalmic in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Latanoprostene Bunod Ophthalmic went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1988390 1 dose form · 1 strength
-
Dose form (SCDF) Ophthalmic Solution RxCUI 1988393In current FDA listingsClinical drug / strength (SCD) 0.24 MG/MLRxCUI 1988394
Look up RxCUI 1988390 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Latanoprostene Bunod Ophthalmic is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Latanoprostene Bunod Ophthalmic belongs to the Prostaglandin analogues class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Bausch & Lomb Incorporated is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.